NDADENTALPOWDER, EXTENDED RELEASE
Approved
Feb 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
ARESTIN (minocycline hydrochloride) by Fosun Pharma is mechanism of action the mechanism of action of arestin as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis is unknown. Approved for periodontitis. First approved in 2001.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARESTIN is a minocycline hydrochloride powder formulation administered as a dental adjunct to scaling and root planing for adult periodontitis. The mechanism of action is unknown, but minocycline is a tetracycline-class antibiotic with broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria. It is used as a localized subgingival treatment to reduce pocket depth in periodontal disease.
$6MPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with modest Part D utilization; brand teams should expect resource constraints and transition planning as LOE approaches.
Mechanism of Action
Mechanism of Action The mechanism of action of ARESTIN as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis is unknown.
Indications (1)
Clinical Trials (1)
Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel
Started Nov 2014
47 enrolled
Acute PainBreast CarcinomaPeripheral Neuropathy
Career Relevance
ARESTIN shows minimal linked career activity in available data, reflecting its niche dental/periodontal market and approaching LOE status. Roles available are likely regional, limited-scope, and focused on compliance and cost management rather than growth initiatives.
Worked on ARESTIN at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.